Industry News

Investment in Ontario drug discovery research will help develop new cancer medicines for patients

05/16/2023

OICR announces support for five projects through its Cancer Therapeutics Innovation Pipeline (CTIP) Excerpt from the Press Release: Ontario research teams investigating new ways to treat cancer are taking the crucial next steps to bring their discoveries to patients thanks to support from the Ontario Institute for Cancer Research (OICR). OICR announced it is funding…

Read More

Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain

05/15/2023

Excerpt from the Press Release: PALO ALTO, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced complete enrollment in…

Read More

Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa

05/12/2023

Excerpt from the Press Release: SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) — Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed patient enrollment ahead of schedule in its Phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation…

Read More

Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)

05/11/2023

Excerpt from the Press Release: BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful safety review of the 10 mg dry powder dose safety cohort from the…

Read More

Artificial intelligence identifies anti-aging drug candidates targeting ‘zombie’ cells

05/10/2023

Integrated Biosciences’ new platform has potential to fuel advances in senolytic anti-aging compounds and longevity research AI-driven platform built on work pioneered at MIT identifies three candidates with comparable efficacy and superior medicinal chemistry relative to current investigational compounds Treatment of aged mice reduced number of senescent ‘zombie’ cells and lowered expression of senescence-associated genes…

Read More

New Enterade Clinical Study Demonstrates Fewer Stopped Treatments and Lower GI Side Effects for Cancer Patients

05/02/2023

Baptist Health Cancer Care Abstract to be presented at Oncology Nursing Society Annual Symposium Excerpt from the Press Release: NORWOOD, Mass., April 27, 2023 /PRNewswire/ — Entrinsic Bioscience is pleased to announce the upcoming poster session on the role of Enterade® Advanced Oncology Formula in reducing adverse gastrointestinal side effects for patients undergoing cancer treatment. The…

Read More

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

05/01/2023

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the first patient has been dosed at City of Hope…

Read More

Anticipating the Future: A Guide to Smart eClinical Technology Investments

04/28/2023

The landscape of clinical research is constantly evolving, and businesses need to keep up with the latest technology to remain competitive. However, investing in eClinical technology is not just about finding a solution for current needs, it’s equally important to think ahead and ensure that your technology investment can adapt and scale to meet future…

Read More

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

04/20/2023

Excerpt from the Press Release: MALVERN, Pa., April 14, 2023 (GLOBE NEWSWIRE) —  Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of…

Read More

Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

04/14/2023

Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the United Kingdom in the Company’s Phase 2…

Read More